SCHEMBL22215490

SCHEMBL22215490

CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 15/20 0.75
▸ BRD4 O60885 14/20 0.75
▸ ALK Q9UM73 6/20 0.75
▸ PLK3 Q9H4B4 5/20 0.74
▸ TAF1 P21675 4/20 0.74
▸ PRKD3 O94806 3/20 0.74
▸ CLK2 P49760 3/20 0.74
▸ PTK2 Q05397 3/20 0.74
▸ CAMK2G Q13555 3/20 0.74
▸ CAMK2D Q13557 3/20 0.74
▸ PRKD2 Q9BZL6 3/20 0.74
▸ CSNK1G1 Q9HCP0 3/20 0.74
▸ CSNK1G3 Q9Y6M4 3/20 0.74
▸ BRDT Q58F21 3/20 0.74
▸ PLK2 Q9NYY3 3/20 0.74
▸ DAPK3 O43293 2/20 0.74
▸ CHEK2 O96017 2/20 0.74
▸ EGFR P00533 2/20 0.74
▸ FES P07332 2/20 0.74
▸ PHKG2 P15735 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27361172 0.87 PLK1 (0.74) PLK1BRD4ALKPLK3TAF1
SCHEMBL27361472 0.87 PLK1 (0.74) PLK1BRD4ALKPLK3TAF1
SCHEMBL27361186 0.87 PLK1 (0.74) PLK1BRD4ALKPLK3TAF1
Bi-2536 SCHEMBL29644993 0.86 BRD4 (0.99) PLK1BRD4ALKPLK3TAF1
Bi-2536 SCHEMBL16984416 0.85 BRD4 (1.00) PLK1BRD4ALKPLK3TAF1
Bi-2536 SCHEMBL614114 0.85 BRD4 (1.00) PLK1BRD4ALKPLK3TAF1
Bi-2536 SCHEMBL372489 0.85 BRD4 (1.00) PLK1BRD4ALKPLK3TAF1
Bi-2536 SCHEMBL29395966 0.85 BRD4 (1.00) PLK1BRD4ALKPLK3TAF1
SCHEMBL20732052 0.85 PLK1 (0.77) PLK1BRD4ALKPLK3TAF1
SCHEMBL28985022 0.84 BRD4 (0.81) PLK1BRD4ALKPLK3TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020146440-A1 ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING MULTIPLE MYELOMA CELGENE CORPORATION (US) 2020-07-16 — — WO disclosed
Send feedback